Curso de Medicina; Universidade Federal do Tocantins; Palmas, Brazil.
Bioengineered. 2013 Sep-Oct;4(5):305-12. doi: 10.4161/bioe.24666. Epub 2013 Apr 22.
Cancer is one of the most important health problems because many cases are difficult to prevent. Cancer still has unknown mechanisms of pathogenesis, and its capacity to produce temporary or permanent damage, besides death, is very high. Although many anticancer therapies are available, finding a cure for cancer continues to be a difficult task. Thus, many efforts have been made to develop more effective treatments, such as immunotherapy based on a new class of tumor-specific products that are produced using recombinant DNA technology. These recombinant products are used with the main objectives of killing the tumor and stimulating immune cells to respond to the cancer cells. The principal recombinant products in anticancer therapy are immunostimulants, vaccines, antibodies, immunotoxins and fusion proteins. This review focuses on the general aspects of these genetically engineered products, their clinical performance, current advances and future prospects for this type of anticancer therapy.
癌症是最重要的健康问题之一，因为许多病例难以预防。癌症的发病机制仍然未知，其造成暂时或永久性损伤的能力非常高，除了死亡之外。虽然有许多抗癌疗法可用，但找到治愈癌症的方法仍然是一项艰巨的任务。因此，人们做出了许多努力来开发更有效的治疗方法，例如基于使用重组 DNA 技术生产的新型肿瘤特异性产品的免疫疗法。这些重组产品主要用于杀死肿瘤和刺激免疫细胞对癌细胞作出反应。在抗癌治疗中主要的重组产品是免疫刺激剂、疫苗、抗体、免疫毒素和融合蛋白。本综述重点介绍了这些基因工程产品的一般方面、它们的临床表现、当前进展以及这种类型的抗癌治疗的未来前景。
